During the recent session, Amneal Pharmaceuticals, Inc. (NYSE:AMRX)’s traded shares were 859,177, with the beta value of the company hitting 1.34. At the last check, the stock’s price was $6.05, reflecting an intraday loss of -3.9% or -$0.24. The 52-week high for the AMRX share is $7.45, that puts it down -23.14% from that peak though still a striking +52.73% gain since the share price plummeted to a 52-week low of $2.86. The company’s market capitalization is $893.53 Million, and the average intraday trading volume over the past 10 days was 1.3 Million shares, and the average trade volume was 2.13 Million shares over the past three months.
Amneal Pharmaceuticals, Inc. (AMRX) received a consensus recommendation of Overweight from analysts. That translates to a mean rating of 2.4. AMRX has a Sell rating from 1 analyst(s) out of 11 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 5 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.18.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX): Trading Information
Amneal Pharmaceuticals, Inc. (AMRX) registered a -3.9% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 12.86% in intraday trading to $6.88- this Monday, Apr 05, hitting a weekly high. The stock’s 5-day price performance is -10.92%, and it has moved by 7.05% in 30 days. Based on these gigs, the overall price performance for the year is 31.18%. The short interest in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) is 5.6 Million shares and it means that shorts have 2.63 day(s) to cover.
The consensus price target of analysts on Wall Street is $6.22, which implies an increase of 2.81% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $9 respectively. As a result, AMRX is trading at a discount of 48.76% off the target high and -50.41% off the low.
Amneal Pharmaceuticals, Inc. (AMRX) projections and forecasts
Statistics show that Amneal Pharmaceuticals, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Amneal Pharmaceuticals, Inc. (AMRX) shares have gone up +52.3% during the last six months, with a year-to-date growth rate more than the industry average at 25.4% against 16.9%. Yet analysts are winding down their growth forecast for the fiscal year 2021. Revenue is predicted to decline -10% this quarter and then jump 46.2% in the quarter after that. In the rating firms’ projections, revenue will increase 7.4% compared to the previous financial year.
Revenue for the current quarter is expected to be $514.73 Million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $527.32 Million by the end of June 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarter totaled $498.53 Million. In this case, analysts expect current quarter sales to grow by 3.2%.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated -17.5%. While earnings are projected to return 95.4% in 2021, the next five years will return -12.1% per annum.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Amneal Pharmaceuticals, Inc. (NYSE:AMRX)’s Biggest Investors
Amneal Pharmaceuticals, Inc. insiders own 10.29% of total outstanding shares while institutional holders control 68.26%, with the float percentage being 76.1%. Fosun International Ltd is the largest shareholder of the company, while 194 institutions own stock in it. As of Dec 30, 2020, the company held over 21.52 Million shares (or 14.5% of all shares), a total value of $98.35 Million in shares.
The next largest institutional holding, with 16.21 Million shares, is of Tpg Group Holdings (sbs) Advisors, Inc.’s that is approximately 10.92% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $74.1 Million.
Also, the Mutual Funds coming in first place with the largest holdings of Amneal Pharmaceuticals, Inc. (AMRX) shares are Vanguard Specialized-Health Care Fund and Vanguard Total Stock Market Index Fund. Data provided on Oct 30, 2020 indicates that Vanguard Specialized-Health Care Fund owns about 9,306,210 shares. This amounts to just over 6.27 percent of the company’s overall shares, with a $38.71 Million market value. The same data shows that the other fund manager holds slightly less at 3.38 Million, or about 2.28% of the stock, which is worth about $15.44 Million.